MCID: NDL001
MIFTS: 45

Nodular Malignant Melanoma

Categories: Cancer diseases, Rare diseases, Skin diseases

Aliases & Classifications for Nodular Malignant Melanoma

MalaCards integrated aliases for Nodular Malignant Melanoma:

Name: Nodular Malignant Melanoma 12 15
Nodular Melanoma 12 20 17 71

Classifications:



External Ids:

Disease Ontology 12 DOID:10047
NCIt 50 C4225
SNOMED-CT 67 2142002
UMLS 71 C0334424

Summaries for Nodular Malignant Melanoma

Disease Ontology : 12 A melanoma that is characterized as highly aggressive and manifests as a uniform blue-black, blue-red, or amelanotic nodule.

MalaCards based summary : Nodular Malignant Melanoma, also known as nodular melanoma, is related to lentigo maligna melanoma and pigmented basal cell carcinoma. An important gene associated with Nodular Malignant Melanoma is NRAS (NRAS Proto-Oncogene, GTPase), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Ganciclovir and Anti-Infective Agents have been mentioned in the context of this disorder. Affiliated tissues include skin, lymph node and brain, and related phenotypes are Decreased substrate adherent cell growth and Decreased substrate adherent cell growth

Wikipedia : 74 Nodular melanoma (NM) is the most aggressive form of melanoma. It tends to grow more rapidly in... more...

Related Diseases for Nodular Malignant Melanoma

Diseases related to Nodular Malignant Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 306)
# Related Disease Score Top Affiliating Genes
1 lentigo maligna melanoma 30.6 MLANA MITF MC1R
2 pigmented basal cell carcinoma 30.5 MLANA MITF
3 amelanotic melanoma 30.1 TYR MLANA KIT BRAF
4 hereditary melanoma 30.1 CDKN2A CDK4
5 acral lentiginous melanoma 30.0 NRAS MC1R KIT HRAS CDKN2A BRAF
6 spitz nevus 30.0 TP53 HRAS CDKN2A BRAF
7 skin benign neoplasm 29.9 TYR MLANA HRAS BRAF
8 basal cell carcinoma 29.1 TYR TP53 MC1R KIT CDKN2A CCND1
9 renal cell carcinoma, nonpapillary 28.4 TP53 NRAS MITF MIR23B KIT HRAS
10 neuroblastoma 28.4 TP53 NRAS MIR23B KIT HRAS CDKN2A
11 sarcoma 28.2 TP53 NRAS MTAP KIT HRAS CDK4
12 skin carcinoma 27.6 TYR TP53 NRAS MLANA MITF MC1R
13 melanoma 27.5 TYR TP53 NRAS MTAP MLANA MITF
14 skin melanoma 27.2 TYR TP53 NRAS MTAP MLANA MITF
15 ovarian melanoma 10.4 NRAS MLANA
16 trachea carcinoma in situ 10.4 HRAS CDKN2A
17 anal canal paget's disease 10.4 MLANA CDKN2A
18 sensory organ benign neoplasm 10.4 NRAS MLANA
19 gallbladder melanoma 10.4 MLANA MITF
20 cervical adenoid cystic carcinoma 10.4 KIT CDKN2A
21 melphalan allergy 10.4 NRAS BRAF
22 phakomatosis cesioflammea 10.4 GNAQ GNA11
23 ciliary body cancer 10.4 TYR MLANA
24 melanoacanthoma 10.4 TYR MLANA
25 halo nevi 10.4 TYR MLANA
26 superficial spreading melanoma 10.4
27 spinal cord melanoma 10.4 TYR MLANA
28 laryngeal small cell carcinoma 10.4 KIT CDKN2A
29 mediastinum liposarcoma 10.4 CDKN2A CDK4
30 maxillary sinus benign neoplasm 10.4 KIT CDKN2A
31 diffuse meningeal melanocytosis 10.4 TYR MLANA
32 benign perivascular tumor 10.4 MLANA KIT
33 small intestine leiomyoma 10.3 MLANA KIT
34 gastric liposarcoma 10.3 KIT CDK4
35 core binding factor acute myeloid leukemia 10.3 NRAS KIT HRAS
36 skin sarcoma 10.3 MLANA KIT
37 myelodysplastic/myeloproliferative neoplasm 10.3 NRAS KIT HRAS
38 cutaneous ganglioneuroma 10.3 MITF KIT
39 uterus perivascular epithelioid cell tumor 10.3 MLANA MITF
40 melanoma, cutaneous malignant 8 10.3 TYR MITF
41 malignant choroid melanoma 10.3 MLANA MITF
42 childhood acute myeloid leukemia 10.3 NRAS KIT HRAS
43 pancreas sarcoma 10.3 CDKN2A CDK4
44 acneiform dermatitis 10.3 NRAS HRAS BRAF
45 meningeal melanocytoma 10.3 MLANA GNAQ GNA11
46 hypomelanosis of ito 10.3 NRAS GNAQ GNA11
47 mongolian spot 10.3 MLANA GNAQ GNA11
48 ochronosis 10.3 TYR MITF MC1R
49 benign struma ovarii 10.3 NRAS HRAS BRAF
50 nevus, epidermal 10.3 NRAS HRAS GNAQ

Graphical network of the top 20 diseases related to Nodular Malignant Melanoma:



Diseases related to Nodular Malignant Melanoma

Symptoms & Phenotypes for Nodular Malignant Melanoma

GenomeRNAi Phenotypes related to Nodular Malignant Melanoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased substrate adherent cell growth GR00193-A-1 9.23 KIT
2 Decreased substrate adherent cell growth GR00193-A-2 9.23 CDK4 KIT
3 Decreased substrate adherent cell growth GR00193-A-3 9.23 BRAF CDK4
4 Decreased substrate adherent cell growth GR00193-A-4 9.23 BRAF CDK4 KIT

MGI Mouse Phenotypes related to Nodular Malignant Melanoma:

46 (show all 24)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.46 BRAF CCND1 CDK4 CDKN2A DIS3 GNA11
2 growth/size/body region MP:0005378 10.42 BRAF CCND1 CDK4 CDKN2A GNA11 GNAQ
3 homeostasis/metabolism MP:0005376 10.4 ABCB5 BRAF CCND1 CDK4 CDKN2A GNA11
4 cardiovascular system MP:0005385 10.39 BRAF CCND1 CDK4 CDKN2A GNA11 GNAQ
5 craniofacial MP:0005382 10.38 BRAF CCND1 CDK4 GNA11 GNAQ HRAS
6 integument MP:0010771 10.38 BRAF CCND1 CDK4 CDKN2A GNA11 GNAQ
7 endocrine/exocrine gland MP:0005379 10.36 BRAF CCND1 CDK4 CDKN2A GNA11 GNAQ
8 immune system MP:0005387 10.36 BRAF CCND1 CDK4 CDKN2A GNA11 GNAQ
9 mortality/aging MP:0010768 10.34 BRAF CCND1 CDK4 CDKN2A DIS3 GNA11
10 embryo MP:0005380 10.24 BRAF CDK4 CDKN2A KIT MITF MTAP
11 hearing/vestibular/ear MP:0005377 10.22 BRAF GNA11 GNAQ KIT MC1R MITF
12 nervous system MP:0003631 10.21 ABCB5 BRAF CCND1 CDK4 CDKN2A GNA11
13 digestive/alimentary MP:0005381 10.2 BRAF CCND1 CDK4 CDKN2A HRAS KIT
14 limbs/digits/tail MP:0005371 10.18 BRAF GNA11 GNAQ KIT MC1R MITF
15 liver/biliary system MP:0005370 10.16 BRAF CDK4 CDKN2A GNA11 KIT MITF
16 neoplasm MP:0002006 10.16 BRAF CCND1 CDK4 CDKN2A HRAS KIT
17 pigmentation MP:0001186 10.13 ABCB5 BRAF CDK4 CDKN2A GNA11 GNAQ
18 normal MP:0002873 10.11 BRAF CCND1 CDK4 GNA11 GNAQ HRAS
19 no phenotypic analysis MP:0003012 10.1 CDKN2A HRAS KIT MC1R MITF MLANA
20 muscle MP:0005369 10.08 BRAF CDK4 CDKN2A GNA11 GNAQ HRAS
21 renal/urinary system MP:0005367 9.91 BRAF CDK4 GNA11 GNAQ HRAS KIT
22 respiratory system MP:0005388 9.81 BRAF CCND1 CDKN2A GNA11 GNAQ HRAS
23 skeleton MP:0005390 9.73 BRAF CCND1 CDK4 CDKN2A GNA11 GNAQ
24 vision/eye MP:0005391 9.36 ABCB5 BRAF CCND1 CDK4 CDKN2A DIS3

Drugs & Therapeutics for Nodular Malignant Melanoma

Drugs for Nodular Malignant Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):


# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ganciclovir Approved, Investigational Phase 1 82410-32-0 3454
2 Anti-Infective Agents Phase 1
3 Antiviral Agents Phase 1
4 Ganciclovir triphosphate Phase 1

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 A Phase I Study of Intralesional Administration of an Adenovirus Vector Expressing the HSV-1 Thymidine Kinase Gene (AdV.RSV-TK) in Combination With Escalating Doses of Ganciclovir in Patients With Cutaneous Metastatic Malignant Melanoma Completed NCT00005057 Phase 1 ganciclovir
2 Melanoma Family Case-Control Study Protocol Unknown status NCT00445783

Search NIH Clinical Center for Nodular Malignant Melanoma

Genetic Tests for Nodular Malignant Melanoma

Anatomical Context for Nodular Malignant Melanoma

MalaCards organs/tissues related to Nodular Malignant Melanoma:

40
Skin, Lymph Node, Brain, Breast, Bone Marrow, Kidney, Tonsil

Publications for Nodular Malignant Melanoma

Articles related to Nodular Malignant Melanoma:

(show top 50) (show all 620)
# Title Authors PMID Year
1
18F-Fluciclovine-Avid Mediastinal Lymph Node Metastasis of Cutaneous Malignant Melanoma. 61
33031240 2021
2
Nodular melanoma in an MITF p.E318K carrier patient: The Wolf in Little Red Riding Hood. 61
32895944 2021
3
Regional Lymph Node Metastases in Cutaneous Melanoma: A Single-Center Analysis from Southeast Europe. 61
33586532 2021
4
Skin melanoma deaths within 1 or 3 years from diagnosis in Europe. 61
33497469 2021
5
Regional lymph node infiltration and thick lesions are associated with poor prognosis in high-risk resected melanomas: A retrospective cohort study. 61
33456772 2021
6
Immunohistochemical study of CD117 in various cutaneous melanocytic lesions. 61
33363589 2021
7
Subtyping Cutaneous Melanoma Matters. 61
33409460 2020
8
Dermatoscopy of melanoma according to type, anatomic site and stage: a 2020 update. 61
33314891 2020
9
S-100 protein and SOX10-positive breast carcinoma mimicking metastatic melanoma. 61
32710508 2020
10
Angiosarcomatous transdifferentiation of metastatic melanoma. 61
32865830 2020
11
Giant nodular melanoma of the nose in a 78-year-old female refusing complete excision. 61
32700784 2020
12
Cauliflower-like exophytic mass on the skin: polypoid melanoma. Clinical, dermoscopic, and histologic features. 61
33041156 2020
13
Dermatoscopic features of thin (≤2 mm Breslow thickness) vs. thick (>2 mm Breslow thickness) nodular melanoma and predictors of nodular melanoma versus nodular non-melanoma tumours: a multicentric collaborative study by the International Dermoscopy Society. 61
32654237 2020
14
Evaluation of two different mutations in codon 12 of NRAS gene in ulcerated penile mucosal nodular malignant melanoma pT4b of the 90-year-old man in perspective of targeted therapy of NRAS-mutated advanced melanomas. 61
32735072 2020
15
Progression of nodular malignant melanoma to metastatic amelanotic melanoma in 3 years: An unusual event. 61
32713107 2020
16
Defining the Prognostic Role of MicroRNAs in Cutaneous Melanoma. 61
32275975 2020
17
'Inverse association between the total naevus count and melanoma thickness'. 61
32171040 2020
18
Management of pembrolizumab-induced steroid refractory mucositis with infliximab: A case report. 61
33024767 2020
19
Clinical and Demographic Profile of Cutaneous Melanoma: Pakistani Perspective. 61
33330006 2020
20
Desmoplastic Melanoma as a Diagnostic Pitfall. 61
32650855 2020
21
Clinicopathological and dermoscopic features of amelanotic and hypomelanotic melanoma: a retrospective multicentric study. 61
32726478 2020
22
PET-guided Switch from Immunotherapy to Targeted Therapy in a Metastatic Melanoma Patient: a personalized approach. 61
32614358 2020
23
[Three independent melanomas over a span of 2 years in a 31-year-old man-a case report]. 61
32333040 2020
24
Leser-Trélat sign as a rare manifestation of cutaneous melanoma. 61
32685126 2020
25
A retrospective study of malignant melanoma from a tertiary care centre in Saudi Arabia from 2004 to 2016. 61
31256363 2020
26
The anatomic distribution of cutaneous melanoma: A detailed study of 5141 lesions. 61
31880825 2020
27
BRAF, KIT, and NRAS Mutations of Acral Melanoma in White Patients. 61
32017841 2020
28
[Melanoma within tattoos: Two cases and a systematic literature review]. 61
31812363 2020
29
Malignant Melanoma of the Vulva and Vagina: A US Population-Based Study of 1863 Patients. 61
31784896 2020
30
BRAF V600 mutation profiling in primary skin nodular melanoma in Indonesia: an analysis using high resolution pyrosequencing. 61
32188503 2020
31
Worse survival of invasive melanoma patients in men and "de novo" lesions. 61
32057507 2020
32
Matrix metalloproteinases MMP-1, MMP-2, and MMP-13 are overexpressed in primary nodular melanoma. 61
31677173 2020
33
Clinical, pathological and dermoscopic phenotype of MITF p.E318K carrier cutaneous melanoma patients. 61
32054529 2020
34
Frequency of mutations in BRAF, NRAS, and KIT in different populations and histological subtypes of melanoma: a systemic review. 61
31274706 2020
35
Epidemiology and Survival Outcomes for Eyelid Primary Malignant Melanoma: An Analysis of 1397 Cases in the SEER Database. 61
33520295 2020
36
Gender Differences of NLRP1 Inflammasome in Mouse Model of Alzheimer's Disease. 61
33328952 2020
37
Rapid Dermoscopic Changes in Nodular Melanoma. 61
31921503 2020
38
A Preliminary Study for Quantitative Assessment with HFUS (High- Frequency Ultrasound) of Nodular Skin Melanoma Breslow Thickness in Adults Before Surgery: Interdisciplinary Team Experience. 61
31589132 2020
39
Distinct Clinicopathological and Prognostic Features of Thin Nodular Primary Melanomas: An International Study from 17 Centers. 61
30863861 2019
40
A comprehensive evaluation of pathogenic mutations in primary cutaneous melanomas, including the identification of novel loss-of-function variants. 61
31745173 2019
41
Multiple Thick Nodular Melanoma: Differentiating Multiple Primaries from the Metastasis of a Previous Single Melanoma 61
31446748 2019
42
Acral melanoma: correlating the clinical presentation to the mutational status. 61
29512974 2019
43
Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm. 61
31590677 2019
44
Paediatric melanoma: clinical update, genetic basis, and advances in diagnosis. 61
31204309 2019
45
Reproductive factors and risk of melanoma: a population-based cohort study. 61
30748007 2019
46
IRF4 rs12203592*T/T genotype is associated with nodular melanoma. 61
31246726 2019
47
Histopathologic variables differentially affect melanoma survival by age at diagnosis. 61
30706692 2019
48
Amelanotic melanoma. 61
30672881 2019
49
Matrical carcinoma with melanocytic hyperplasia mimicking nodular melanoma in an elderly Mexican male. 61
30785652 2019
50
A nomogram for predicting survival in patients with nodular melanoma: A population-based study. 61
31192966 2019

Variations for Nodular Malignant Melanoma

Expression for Nodular Malignant Melanoma

Search GEO for disease gene expression data for Nodular Malignant Melanoma.

Pathways for Nodular Malignant Melanoma

Pathways related to Nodular Malignant Melanoma according to GeneCards Suite gene sharing:

(show top 50) (show all 77)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.87 TP53 NRAS KIT HRAS GNA11 CDKN2A
2
Show member pathways
13.75 TP53 NRAS KIT HRAS GNA11 CDKN2A
3
Show member pathways
13.26 TP53 NRAS HRAS GNAQ GNA11 CCND1
4
Show member pathways
13.11 TP53 NRAS KIT HRAS GNA11 BRAF
5
Show member pathways
13.04 TP53 NRAS KIT HRAS CDK4 CCND1
6
Show member pathways
13.03 TP53 NRAS HRAS GNAQ GNA11 CDK4
7
Show member pathways
12.92 NRAS HRAS GNAQ GNA11 CCND1 BRAF
8
Show member pathways
12.9 TP53 NRAS HRAS GNAQ GNA11 CDKN2A
9
Show member pathways
12.85 NRAS KIT HRAS GNAQ GNA11 BRAF
10
Show member pathways
12.81 TP53 NRAS KIT HRAS CDKN2A CDK4
11 12.8 TP53 NRAS KIT HRAS BRAF
12
Show member pathways
12.77 NRAS KIT HRAS GNAQ BRAF
13
Show member pathways
12.68 NRAS HRAS GNAQ GNA11 CCND1
14
Show member pathways
12.67 TP53 NRAS HRAS CCND1 BRAF
15
Show member pathways
12.67 TP53 NRAS KIT HRAS CDKN2A CDK4
16 12.53 TP53 NRAS MIR23B HRAS CDKN2A CCND1
17
Show member pathways
12.53 TP53 NRAS MITF HRAS CDKN2A CDK4
18
Show member pathways
12.48 NRAS HRAS GNAQ GNA11 CCND1 BRAF
19
Show member pathways
12.42 TP53 CDKN2A CDK4 CCND1
20 12.42 TP53 NRAS MITF KIT HRAS GNAQ
21 12.41 TP53 CDKN2A CDK4 CCND1
22
Show member pathways
12.39 TP53 CDKN2A CDK4 CCND1
23
Show member pathways
12.37 HRAS GNAQ GNA11 CCND1
25
Show member pathways
12.35 TP53 NRAS HRAS BRAF
26 12.33 TP53 NRAS HRAS CCND1 BRAF
27 12.33 TP53 NRAS HRAS CDKN2A CDK4 CCND1
28 12.26 TP53 NRAS HRAS CDKN2A CDK4 CCND1
29
Show member pathways
12.24 TP53 NRAS HRAS CDK4 CCND1 BRAF
30
Show member pathways
12.23 TP53 NRAS HRAS BRAF
31 12.2 TP53 CDK4 CCND1 BRAF
32
Show member pathways
12.19 TP53 NRAS HRAS BRAF
33
Show member pathways
12.17 TYR NRAS MITF MC1R KIT HRAS
34
Show member pathways
12.13 NRAS HRAS CCND1 BRAF
35 12.13 NRAS HRAS GNAQ CCND1
36
Show member pathways
12.1 NRAS HRAS CDK4 CCND1
37 12.1 TP53 NRAS HRAS CDKN2A CDK4 CCND1
38
Show member pathways
12.08 HRAS GNAQ GNA11 BRAF
39
Show member pathways
12.08 TP53 NRAS HRAS GNAQ GNA11
40 12.06 TP53 NRAS HRAS CCND1
41 12.05 TP53 MIR23B CDK4 CCND1
42 12.04 TP53 NRAS HRAS GNAQ
43 12.02 NRAS HRAS GNAQ BRAF
44 12.01 NRAS HRAS GNAQ BRAF
45
Show member pathways
11.99 NRAS HRAS GNAQ BRAF
46 11.98 TP53 NRAS HRAS CDKN2A CCND1
47 11.97 TP53 HRAS CDKN2A BRAF
48 11.94 NRAS HRAS CDK4 CCND1
49 11.89 TP53 CDK4 CCND1
50 11.88 NRAS HRAS GNAQ GNA11

GO Terms for Nodular Malignant Melanoma

Cellular components related to Nodular Malignant Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.5 TYR TP53 SEC23IP MTAP MITF MC1R

Biological processes related to Nodular Malignant Melanoma according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 regulation of cell proliferation GO:0042127 9.65 TP53 MITF KIT CDK4 BRAF
2 positive regulation of phospholipase C activity GO:0010863 9.51 KIT HRAS
3 positive regulation of gene expression GO:0010628 9.5 TP53 MITF MIR23B KIT HRAS CDKN2A
4 melanin biosynthetic process GO:0042438 9.49 TYR MC1R
5 developmental pigmentation GO:0048066 9.48 KIT GNA11
6 somatic stem cell division GO:0048103 9.46 KIT CDKN2A
7 Ras protein signal transduction GO:0007265 9.46 TP53 NRAS HRAS CDKN2A
8 mitotic G1 DNA damage checkpoint GO:0031571 9.43 TP53 CCND1
9 phototransduction, visible light GO:0007603 9.4 GNAQ GNA11
10 entrainment of circadian clock GO:0009649 9.37 GNAQ GNA11
11 myeloid progenitor cell differentiation GO:0002318 9.32 KIT BRAF
12 pigmentation GO:0043473 8.92 TYR MITF MC1R KIT

Molecular functions related to Nodular Malignant Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleotide binding GO:0000166 9.86 NRAS KIT HRAS GNAQ GNA11 CDK4
2 protein-containing complex binding GO:0044877 9.35 NRAS HRAS CDK4 CCND1 BRAF
3 MDM2/MDM4 family protein binding GO:0097371 9.16 TP53 CDKN2A
4 type 2A serotonin receptor binding GO:0031826 8.62 GNAQ GNA11

Sources for Nodular Malignant Melanoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....